Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)

v3.22.4
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 29, 2022
shares
Sep. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2022
USD ($)
shares
Sep. 30, 2022
USD ($)
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2022
USD ($)
segment
shares
Dec. 31, 2021
USD ($)
Jun. 30, 2022
USD ($)
shares
Number of Operating Segments | segment             2    
Proceeds from Divestiture of Interest in Consolidated Subsidiaries             $ 17,824    
Net sales       $ 271,581   $ 269,276 541,236 $ 526,995  
Gain on sale of Eminence             $ 11,682 $ 0  
Common stock, shares authorized (in shares) | shares 400,000,000     400,000,000 100,000,000   400,000,000   400,000,000
Declared stock split 4                
Additional shares | shares 3                
Changzhou Eminence Biotechnology [Member]                  
Proceeds from Divestiture of Interest in Consolidated Subsidiaries   $ 17,800              
Goodwill, Impairment Loss                 $ 8,300
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)                 8,600
Protein Sciences [Member]                  
Pre-tax restructuring charges       $ 800          
Protein Sciences [Member] | Changzhou Eminence Biotechnology [Member]                  
Net sales         $ 2,000       4,600
Diagnostics and Genomics [Member]                  
Pre-tax restructuring charges                 1,400
Wilson Wolf Corporation [Member]                  
Payments to Acquire Investments, Total     $ 25,000       $ 25,000    
Wilson Wolf Corporation [Member] | First Part of Forward Contract [Member]                  
Forward Contract, Milestone, Annual Revenue Required       92,000     92,000    
Forward Contract, Milestone, Annual EBITDA       55,000     55,000    
Forward Contract Payment       $ 231,000     $ 231,000    
Wilson Wolf Corporation [Member] | First Part of Forward Contract Triggered [Member]                  
Noncontrolling Interest, Ownership Percentage by Parent       19.90%     19.90%    
Wilson Wolf Corporation [Member] | Second Part of Forward Contract [Member]                  
Forward Contract, Milestone, Annual Revenue Required       $ 226,000     $ 226,000    
Forward Contract, Milestone, Annual EBITDA       136,000     136,000    
Forward Contract, Additional Investment       $ 1,000,000     $ 1,000,000    
Forward Contract, Milestone, Multiple for Total Expected Payments       4.4     4.4    
QT Holdings Corporation [Member] | Protein Sciences [Member]                  
Pre-tax restructuring charges       $ 0     $ 2,200    
Changzhou Eminence Biotechnology [Member]                  
Inventory Write-down                 900
Asset Impairment Charges, Total                 $ 900
Changzhou Eminence Biotechnology [Member] | Nonoperating Income (Expense) [Member]                  
Gain on sale of Eminence         $ 11,700